Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Following Chemoradiotherapy in pMMR/MSS Rectal Cancer
NCT04833387Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in rectal cancer, sponsored by Sun Yat-sen University. Started Jan 2021; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04833387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833387.